Economic costs of diabetes in the US in 2002
- PMID: 12610059
- DOI: 10.2337/diacare.26.3.917
Economic costs of diabetes in the US in 2002
Abstract
Objective: Diabetes is the fifth leading cause of death by disease in the U.S. Diabetes also contributes to higher rates of morbidity-people with diabetes are at higher risk for heart disease, blindness, kidney failure, extremity amputations, and other chronic conditions. The objectives of this study were 1). to estimate the direct medical and indirect productivity-related costs attributable to diabetes and 2). to calculate and compare the total and per capita medical expenditures for people with and without diabetes.
Research design and methods: Medical expenditures were estimated for the U.S. population with and without diabetes in 2002 by sex, age, race/ethnicity, type of medical condition, and health care setting. Health care use and total health care expenditures attributable to diabetes were estimated using etiological fractions, calculated based on national health care survey data. The value of lost productivity attributable to diabetes was also estimated based on estimates of lost workdays, restricted activity days, prevalence of permanent disability, and mortality attributable to diabetes. RESULTS-Direct medical and indirect expenditures attributable to diabetes in 2002 were estimated at 132 billion US dollars. Direct medical expenditures alone totaled 91.8 billion US dollars and comprised 23.2 billion US dollars for diabetes care, 24.6 billion US dollars for chronic complications attributable to diabetes, and 44.1 billion US dollars for excess prevalence of general medical conditions. Inpatient days (43.9%), nursing home care (15.1%), and office visits (10.9%) constituted the major expenditure groups by service settings. In addition, 51.8% of direct medical expenditures were incurred by people >65 years old. Attributable indirect expenditures resulting from lost workdays, restricted activity days, mortality, and permanent disability due to diabetes totaled 39.8 billion US dollars. U.S. health expenditures for the health care components included in the study totaled 865 billion US dollars, of which 160 billion US dollars was incurred by people with diabetes. Per capita medical expenditures totaled 13243 US dollars for people with diabetes and 2560 US dollars for people without diabetes. When adjusting for differences in age, sex, and race/ethnicity between the population with and without diabetes, people with diabetes had medical expenditures that were approximately 2.4 times higher than expenditures that would be incurred by the same group in the absence of diabetes.
Conclusions: The estimated 132 billion US dollars cost likely underestimates the true burden of diabetes because it omits intangibles, such as pain and suffering, care provided by nonpaid caregivers, and several areas of health care spending where people with diabetes probably use services at higher rates than people without diabetes (e.g., dental care, optometry care, and the use of licensed dietitians). In addition, the cost estimate excludes undiagnosed cases of diabetes. Health care spending in 2002 for people with diabetes is more than double what spending would be without diabetes. Diabetes imposes a substantial cost burden to society and, in particular, to those individuals with diabetes and their families. Eliminating or reducing the health problems caused by diabetes through factors such as better access to preventive care, more widespread diagnosis, more intensive disease management, and the advent of new medical technologies could significantly improve the quality of life for people with diabetes and their families while at the same time potentially reducing national expenditures for health care services and increasing productivity in the U.S. economy.
Similar articles
-
Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association.Diabetes Care. 1998 Feb;21(2):296-309. doi: 10.2337/diacare.21.2.296. Diabetes Care. 1998. PMID: 9539999
-
Economic Costs of Diabetes in the U.S. in 2017.Diabetes Care. 2018 May;41(5):917-928. doi: 10.2337/dci18-0007. Epub 2018 Mar 22. Diabetes Care. 2018. PMID: 29567642 Free PMC article.
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
Economic costs of diabetes in the U.S. in 2012.Diabetes Care. 2013 Apr;36(4):1033-46. doi: 10.2337/dc12-2625. Epub 2013 Mar 6. Diabetes Care. 2013. PMID: 23468086 Free PMC article.
-
Economic Costs of Diabetes in the U.S. in 2022.Diabetes Care. 2024 Jan 1;47(1):26-43. doi: 10.2337/dci23-0085. Diabetes Care. 2024. PMID: 37909353 Review.
Cited by
-
Changes in ideal cardiovascular health status and risk of new-onset type 2 diabetes: The Kailuan prospective study.Medicine (Baltimore). 2016 Aug;95(34):e4571. doi: 10.1097/MD.0000000000004571. Medicine (Baltimore). 2016. PMID: 27559955 Free PMC article.
-
The role of endothelial insulin signaling in the regulation of glucose metabolism.Rev Endocr Metab Disord. 2013 Jun;14(2):207-16. doi: 10.1007/s11154-013-9242-z. Rev Endocr Metab Disord. 2013. PMID: 23589150 Review.
-
Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis.Rheumatol Int. 2016 Nov;36(11):1515-1523. doi: 10.1007/s00296-016-3544-x. Epub 2016 Aug 6. Rheumatol Int. 2016. PMID: 27498017
-
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Core Evid. 2008 Jun;3(1):13-30. doi: 10.3355/ce.2008.009. Core Evid. 2008. PMID: 20694081 Free PMC article.
-
Racial and Ethnic Approaches to Community Health (REACH) Detroit partnership: improving diabetes-related outcomes among African American and Latino adults.Am J Public Health. 2005 Sep;95(9):1552-60. doi: 10.2105/AJPH.2005.066134. Epub 2005 Jul 28. Am J Public Health. 2005. PMID: 16051927 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical